Mechanistically modeling peripheral cytokine dynamics following bispecific dosing in solid tumors
Abstract Bispecific antibodies exhibit proven clinical benefit, and many bispecifics are currently in clinical development for oncology. Cytokine release syndrome (CRS) is a common clinical adverse effect observed following CD3‐based bispecific dosing. However, the pathophysiology of CRS is not full...
Main Author: | |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-11-01
|
Series: | CPT: Pharmacometrics & Systems Pharmacology |
Online Access: | https://doi.org/10.1002/psp4.12928 |